Dr. Tanya Siddiqi, MD
Claim this profileCity of Hope Medical Center
Studies Lymphoma
Studies Chronic Lymphocytic Leukemia
8 reported clinical trials
13 drugs studied
Area of expertise
1Lymphoma
CD5 positive
CD19 positive
MYC positive
2Chronic Lymphocytic Leukemia
CD5 positive
CD19 positive
Stage I
Affiliated Hospitals
Clinical Trials Tanya Siddiqi, MD is currently running
CAR T-Cell Therapy
for Brain Lymphoma
This phase I trial tests the safety, side effects, and best dose of intracerebroventricularly (ICV) administered CD19-chimeric antigen receptor (CAR) T cells in treating patients with central nervous system (CNS) lymphoma. CAR T cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, CD19, on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor (CAR). Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. ICV is an injection technique that delivers the CD19-CAR T cells directly into the cerebrospinal fluid (which flows in and around the hollow spaces of the brain and spinal cord, and the thin layers of tissue that cover and protect the brain and spinal cord) in the brain, through a surgically placed catheter. Giving CD19-CAR T cells ICV may be more effective at treating patients with CNS lymphoma than giving them via other methods.
Recruiting1 award Phase 1
JCAR017
for Chronic Leukemia or Lymphoma
This trial tests JCAR017, a therapy using modified immune cells, in adults with hard-to-treat CLL or SLL. It aims to see if these enhanced immune cells can better fight the cancer.
Recruiting1 award Phase 1 & 2
More about Tanya Siddiqi, MD
Clinical Trial Related6 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Tanya Siddiqi, MD has experience with
- Ibrutinib
- Venetoclax
- CD19-CAR T Cells
- Lisocabtagene Maraleucel
- Nivolumab
- Cirmtuzumab
Breakdown of trials Tanya Siddiqi, MD has run
Lymphoma
Chronic Lymphocytic Leukemia
Mantle Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Tanya Siddiqi, MD specialize in?
Tanya Siddiqi, MD focuses on Lymphoma and Chronic Lymphocytic Leukemia. In particular, much of their work with Lymphoma has involved CD5 positive patients, or patients who are CD19 positive.
Is Tanya Siddiqi, MD currently recruiting for clinical trials?
Yes, Tanya Siddiqi, MD is currently recruiting for 4 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Tanya Siddiqi, MD has studied deeply?
Yes, Tanya Siddiqi, MD has studied treatments such as Ibrutinib, Venetoclax, CD19-CAR T Cells.
What is the best way to schedule an appointment with Tanya Siddiqi, MD?
Apply for one of the trials that Tanya Siddiqi, MD is conducting.
What is the office address of Tanya Siddiqi, MD?
The office of Tanya Siddiqi, MD is located at: City of Hope Medical Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.